UBS analyst Michael Yee raised the firm’s price target on Merck (MRK) to $145 from $130 and keeps a Buy rating on the shares. The firm adjusted targets in the pharmaceuticals and biotechnology group as part of a Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck, Daiichi Sankyo announces BLA for I-DXd granted priority review by FDA
- Merck, Daiichi Sankyo granted priority review for ifinatamab deruxtecan BLA
- M&A News: Organon Stock (OGN) Surges 26% on Reported Sun Pharma Bid
- Merck begins tender offer to acquire Terns Pharmaceuticals
- Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial